At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
MLTX MoonLake Immunotherapeutics
Trading 12-09 15:25:49 EST
14.44
-0.63
-4.18%
High15.05Low14.10Vol1.39M
Open14.96D1 Closing15.07Amplitude6.30%
Mkt Cap1.03BTradable Cap583.60MTotal Shares71.37M
T/O20.23MT/O Rate3.44%Tradable Shares40.42M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Moonlake Immunotherapeutics Faces Class Action Lawsuit Over Securities Fraud Allegations
Reuters  ·  12-08 20:47
Moonlake Immunotherapeutics Faces Class Action Lawsuit Over Securities Fraud Allegations
Moonlake Immunotherapeutics Faces Class Action Lawsuit Over Alleged Securities Fraud
Reuters  ·  12-03
Moonlake Immunotherapeutics Faces Class Action Lawsuit Over Alleged Securities Fraud
MoonLake Immunotherapeutics Faces Class Action Lawsuit Alleging Securities Fraud
Reuters  ·  12-02
MoonLake Immunotherapeutics Faces Class Action Lawsuit Alleging Securities Fraud
MoonLake Immunotherapeutics Faces Class Action Lawsuit Over Alleged Securities Fraud
Reuters  ·  11-25
MoonLake Immunotherapeutics Faces Class Action Lawsuit Over Alleged Securities Fraud
MoonLake Immunotherap Is Maintained at Buy by HC Wainwright & Co.
Dow Jones  ·  11-21
MoonLake Immunotherap Is Maintained at Buy by HC Wainwright & Co.
MoonLake price target lowered to $26 from $30 at H.C. Wainwright
TIPRANKS  ·  11-21
MoonLake price target lowered to $26 from $30 at H.C. Wainwright
MoonLake Immunotherapeutics Faces Investor Class Action Over Alleged Securities Fraud
Reuters  ·  11-19
MoonLake Immunotherapeutics Faces Investor Class Action Over Alleged Securities Fraud
Moonlake Immunotherapeutics Faces Class Action Lawsuit Over Alleged Securities Fraud
Reuters  ·  11-12
Moonlake Immunotherapeutics Faces Class Action Lawsuit Over Alleged Securities Fraud
MoonLake Immunotherapeutics Faces Class Action Lawsuit Alleging Securities Fraud
Reuters  ·  11-07
MoonLake Immunotherapeutics Faces Class Action Lawsuit Alleging Securities Fraud
MoonLake Immunotherapeutics Reports Q3 2025 Financial Results
TIPRANKS  ·  11-07
MoonLake Immunotherapeutics Reports Q3 2025 Financial Results
RBC Capital Sticks to Its Hold Rating for MoonLake Immunotherapeutics (MLTX)
TIPRANKS  ·  11-07
RBC Capital Sticks to Its Hold Rating for MoonLake Immunotherapeutics (MLTX)
Stock Track | MoonLake Immunotherapeutics Plummets 5.10% Amid Investor Class Action Lawsuit
Stock Track  ·  11-07
Stock Track | MoonLake Immunotherapeutics Plummets 5.10% Amid Investor Class Action Lawsuit
Wedbush Sticks to Their Buy Rating for MoonLake Immunotherapeutics (MLTX)
TIPRANKS  ·  11-06
Wedbush Sticks to Their Buy Rating for MoonLake Immunotherapeutics (MLTX)
MoonLake Immunotherapeutics: Strong Financials and Promising Clinical Developments Drive Buy Rating
TIPRANKS  ·  11-06
MoonLake Immunotherapeutics: Strong Financials and Promising Clinical Developments Drive Buy Rating
MoonLake Immunotherapeutics: Promising Clinical Trials and Strategic Regulatory Advances Boost Confidence in Sonelokimab
TIPRANKS  ·  11-06
MoonLake Immunotherapeutics: Promising Clinical Trials and Strategic Regulatory Advances Boost Confidence in Sonelokimab
BRIEF-MoonLake Immunotherapeutics Announces Pricing of $75 Million Underwritten Offering
Reuters  ·  11-05
BRIEF-MoonLake Immunotherapeutics Announces Pricing of $75 Million Underwritten Offering
MoonLake Q3 EPS $(1.10) Misses $(0.88) Estimate
Benzinga  ·  11-05
MoonLake Q3 EPS $(1.10) Misses $(0.88) Estimate
MoonLake Immunotherapeutics - Prices 7.1 Mln Class a Ordinary Shares at $10.50 Each
THOMSON REUTERS  ·  11-05
MoonLake Immunotherapeutics - Prices 7.1 Mln Class a Ordinary Shares at $10.50 Each
BRIEF-MoonLake Immunotherapeutics Q3 EPS USD -1.1
Reuters  ·  11-05
BRIEF-MoonLake Immunotherapeutics Q3 EPS USD -1.1
MoonLake Immunotherapeutics reports third quarter 2025 results and announces new clinical trial data
Reuters  ·  11-05
MoonLake Immunotherapeutics reports third quarter 2025 results and announces new clinical trial data

Introduction

Company Name.
MoonLake Immunotherapeutics
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or axial spondyloarthritis. MoonLake Immunotherapeutics was incorporated in 2021 and is headquartered in Zug, Switzerland.
Issue price:
--